Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model

International Journal of Cancer

Volumn 124, Issue 2, 2009, Pages 465-472

  Appleyard, Maria Virginia C L ^a   O'Neill, Mary A ^a   Murray, Karen E ^a   Paulin, Fiona E M ^a   Bray, Susan E ^a   Kernohan, Neil M ^a   Levison, David A ^a   Lane, David P ^a   Thompson, Alastair M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cdk inhibitor; Combination therapy; Seliciclib; Xenograft

Indexed keywords

DOXORUBICIN; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53; ROSCOVITINE; SURVIVIN; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PURINES;

EID: 58249091745     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23938     Document Type: Article

References (48)

1. Esteva FJ, Valero V, Pusztai L, Michaud LB, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001;2:133-46.
2. Rose PG. Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer. Semin Oncol Nurs 2003;19:25-35.
3. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-30.
4. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Mogh-rabi A, et al. The effect of dexrazone on myocardial injury in doxoru-bicin-treated children with acute lymphoblastic leukaemia. N Engl J Med 2004;351:145-53.
5. Sherr CJ. Cancer cell cycle. Science 1996;274:1672-7.
6. Sherr CJ, The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95.
7. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-4
8. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y. Growth suppression by p18, a p16INK4/MTS1-and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8:2939-52.
9. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinase. Nature 1993;366:701-4
10. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Schei-thauer BW. P27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Surg Pathol 1999;154:313-22.
11. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Bio-chem 1997;15:518-26.
12. Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, Sausville EA. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res 1999;59:2566-9.
13. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-20.
14. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 2003; 36:417-25.
15. Whittaker SR, Walton MI, Garret MD, Workman P. The cyclin-de-pendent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblas-toma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004;64:262-72.
16. MacCallum DE, Melville J, Frame S, Anderson S, Gianella-Borradori A, Lane DP, Green SR. Seliciclib (CYC202. R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of. RNA polymer-ase. II-dependent transcription and down-regulation of. Mcl-1. Cancer Res 2005;65:5399-07.
17. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Kle-vernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors; a further update. Biochem J 2007;15:408:297-315.
18. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, et al. In vitro and in vivo antitumour properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
19. Aas T, Borresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Var-haug JE, Akslen LA, Lønning PE. Specific p53 mutations are associ-ated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-14.
20. Bertheau P, Plassa F, Espié M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de Thé H. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002;360:852-4.
21. Soussi T. The p53 tumour suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 2000;910:121-39.
22. Cox LS, Lane DP. Tumour suppressor kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays 1995;17:501-8.
23. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72.
24. Garte AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-46.
25. Thornberry NA, Lazenbnik Y. Caspases: enemies within. Science 1998;281:1312-16.
26. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
27. Yang XH, Sladek TL, Liu X, Butler BR Froelich CJ, Thor AD.Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 2001;61:384-54.
28. Essmann F, Engels IH, Totzke G, Schulze-Osthoff K, Janicke RU. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res 2004;64:7065-72.
29. Mirza A, M McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier Pl, Bishop WR, Nielsen LL, Pickett CB, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613-22.
30. O'Driscoll L, Linehan R, Clynes M. Survivin: role in normal cells and in pathological conditions. Curr Cancer Drug Targets 2003;3:131-52.
31. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-Family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95). Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20.
32. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura1 RA. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005;24:1994-2007.
33. Appleyard VC, O'Neill MA, Murray KE, Bray SE, Thomson G, Ker-nohan NM, Varani J, Zhang J Thompson AM. Activity of MDI-301, a novel synthetic retinoid in xenografts. Anticancer Drugs 2004;19:991-6.
34. Coley HM, Shotton CF, Kokkinos MI, Thomas H. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines. Gynaecol Oncol 2007;105:462-9.
35. Wesierska-Gadek J, Gueorguieva M, Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 2005;4:113-24.
36. Wesierska-Gadek J, Schreiner T, Gueorguieva M, Ranftler C. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells. J Cell Biochem 2006;98:1367-79.
37. Crescenzi E, Palumbo G, Brady HJM. Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy. Clin Cancer Res 2005;11:8158-71.
38. Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 1993;4:533-43.
39. Goormaghtigh E, Ruysschaert JM. Anthracycline glycoside-mem-brane interactions. Biomed Byophys Acta 1984;779:271-88.
40. Martinez R, Garcia CL. The search of DNA-intercalators as antitu-moural drugs: what worked and what did not work. Curr Med Chem 2005;12:127-51.
41. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adri-amycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990;47:210-31.
42. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389:300-5.
43. Chen Q, Fischer A, Reagan JD, Yan LJ, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci USA 1995;92:4337-41.
44. Macip S, Igarashi M, Berggren P, Yu J, Lee SW, Aaronson SA. Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol 2003;23:8576-85.
45. Hsu SL, Chen MC, Chou YH, Hwang GY, Yin SC. Induction of p21(CIP/Waf1) and activation of p34(cdc2) involved in retinoic acid- induced apoptosis in human hepatoma Hep3B cells. Exp Cell Res 1999;248:87-96.
46. Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 1999;18: 3166-72.
47. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
48. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity is related to p21. Cell 1994;78:67-74.